688222.SS Stock Analysis
68
Neutral
Based on Eyestock quantitative analysis, 688222.SS`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
HitGen, Inc. engages in the provision deoxyribonucleic acid encoded compound library (DEL) for research and development of seed and lead compounds. The company is headquartered in Chengdu, Sichuan and currently employs 471 full-time employees. The company went IPO on 2020-04-16. The firm focuses on the research and creation of deoxyribonucleic acid encoded compound library (DEL) technology, research and development of hit compounds and lead compounds. The firm mainly provides DEL screening services, DEL library customization services, chemical synthesis services and transfer of new drug research and development projects. The firm conducts its businesses within the domestic market and to overseas markets.